Bibliographie collaborative AIH – Janvier 2016

Leucémies aiguës

Proposé par Lucille Debus et Ludovic Gabellier, supervisé par Pierre Hirsch. 

  1. Zugmaier, G. et al. Long-term survival and T-cell kinetics in relapsed / refractory ALL patients who achieved MRD response after blinatumomab treatment. 126, 2578–2585 (2015).
  1. Longo, D. L., Hunger, S. P. & Mullighan, C. G. Acute Lymphoblastic Leukemia in Children. N. Engl. J. Med. 373, 1541–1552 (2015)
  1. Jaime-Pérez, J. C. et al. Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era? Clin. Lymphoma Myeloma Leuk. 15, 816–819 (2015).
  1. Fong, C. Y. et al. BET inhibitor resistance emerges from. (2015). doi:10.1038/nature14888
  1. Zhang, J. et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. Engl. J. Med. 151118140202004 (2015). doi:10.1056/NEJMoa1508054
  1. Clappier, E. et al. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children’s Leukemia Group study 58951. Leukemia 2154–2161 (2015). doi:10.1038/leu.2015.134
  1. Molenaar, R. J. et al. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Leukemia 29, 2134–2142 (2015).
  1. Polak, R., de Rooij, B., Pieters, R. & den Boer, M. L. B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment. Blood 126, 2404–2415 (2015).
  1. Garg, M. et al. Pro fi ling of somatic mutations in acute myeloid leukemia with FLT3 -ITD at diagnosis and relapse. 126, 2491–2502 (2015).
  1. Cheng, X. et al. MYELOID NEOPLASIA PKR inhibits the DNA damage response , and is associated with poor survival in AML and accelerated leukemia in NHD13 mice. 126, 1585–1595 (2015).
  1. Röllig, C. et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 16, 1691–1699 (2015).
  1. Song, C. et al. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic ef fi cacy in high-risk leukemia. 126, 1813–1823 (2015).

 

Allogreffe de cellules souches hématopoïétiques

Proposé par Zoé Van de Wyngaert et Dinh Ngoc Mai, supervisé par Régis Peffault De Latour. 

  1. Weber D, Oefner PJ, Hiergeist A, Koestler J, Gessner A, Weber M, et al. Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. Blood. 2015;126(14):1723-8.
  1. Schmid C, Labopin M, Socie G, Daguindau E, Volin L, Huynh A, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. 2015;126(17):2062-9.
  1. Noriega V, Martinez-Laperche C, Buces E, Pion M, Sanchez-Hernandez N, Martin-Antonio B, et al. The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. PloS one. 2015;10(10):e0140454.
  1. Gratwohl A, Pfirrmann M, Zander A, Kroger N, Beelen D, Novotny J, et al. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment. 2015.
  1. Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, et al. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015;33(35):4167-75.
  1. Burns DM, Tierney R, Shannon-Lowe C, Croudace J, Inman C, Abbotts B, et al. Memory B cell reconstitution following allogeneic haematopoietic stem cell transplantation is an EBV-associated transformation event. 2015.
  1. Laura M. Calvi and Daniel C. The hematopoietic stem cell niche in homeostasis and disease, November 26, 2015; Blood: 126 (22).
  1. Granier C, Biard L, Masson E, Porcher R, Peffault de Latour R, Robin M, et al.Impact of the source of hematopoietic stem cell in unrelated transplants: Comparison between 10/10, 9/10-HLA matched donors and cord blood, American journal of hematology, Volume 90, Issue 10, October 2015, 897–903.
  1. Sprangers B, Van Wijmeersch B, Billiau AD. Allogeneic bone marrow transplantation and donor lymphocyte infusion in a mouse model of irradiation-induced myelodysplastic/myeloproliferation syndrome (MD/MPS): evidence for a graft-versus-MD/MPS effect,Leukemia23, 340–349.
  1. Lund TC, Liegel J, Bejanyan N, Orchard PJ, Cao Q, Tolar J, et al. Second allogeneic hematopoietic cell transplantation for graft failure: Poor outcomes for neutropenic graft failure, American journal of hematology, Volume 90, Issue 10, October 2015,892–896.

 

Myélome

Proposé par Alexis Talbot et Floriane Theves, supervisé par Laurent Frenzel. 

  1. Chng WJ, Chung TH, Kumar S, Usmani S, Munshi N, Avet-Loiseau H, Goldschmidt H, Durie B, Sonneveld P. Gene signature combinations improve prognostic stratification of multiple myeloma patients. 2015 Dec 16. doi: 10.1038/leu.2015.341. [Epub ahead of print] PubMed PMID: 26669975.
  1. Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, Tedeschi A, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2015 Dec 13. doi: 10.1111/bjh.13897. [Epub ahead of print] PubMed PMID: 26659815
  1. Dimopoulos MA, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, Derigs HG, Eom H, Belhadj K, Lenain P, Van der Jagt R, Rigaudeau S, Dib M, Hall R, Jardel H, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Leupin N, Chen G, Marek J, Ervin-Haynes A, Facon T. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. 2015 Dec 11. pii: haematol.2015.133629. [Epub ahead of print] PubMed PMID: 26659916
  1. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2015 Dec 3. pii: S1470-2045(15)00464-7. doi: 10.1016/S1470-2045(15)00464-7. [Epub ahead of print] PubMed PMID: 26671818.
  1. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi:       1200/JCO.2014.59.1503. Epub 2015 Aug 17. PubMed PMID:    26282654.
  1. Iriuchishima H, Ozaki S, Konishi J, Matsumoto M, Murayama K, Nakamura F, Yamamoto G, Handa H, Saitoh T, Nagura E, Shimizu K, Nojima Y, Murakami H. Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma. Acta Haematol. 2016;135(2):113-21. doi: 10.1159/000439424. Epub 2015 Oct 28. PubMed PMID: 26505781.
  1. Chretien ML, Corre J, Lauwers-Cances V, Magrangeas F, Cleynen A, Yon E, Hulin C, Leleu X, Orsini-Piocelle F, Blade JS, Sohn C, Karlin L, Delbrel X, Hebraud B, Roussel M, Marit G, Garderet L, Mohty M, Rodon P, Voillat L, Royer B, Jaccard A, Belhadj K, Fontan J, Caillot D, Stoppa AM, Attal M, Facon T, Moreau P, Minvielle S, Avet-Loiseau H. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? 2015 Dec 17;126(25):2713-9. doi: 10.1182/blood-2015-06-650242. Epub 2015 Oct 29. PubMed PMID: 26516228; PubMed Central PMCID: PMC4683332.
  1. Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S. FOXM1 is a therapeutic target for high-risk multiple myeloma. 2015 Dec 9. doi: 10.1038/leu.2015.334. [Epub ahead of print] PubMed PMID: 26648534.
  1. Facon T. Maintenance therapy for multiple myeloma in the era of novel agents. Hematology Am Soc Hematol Educ Program. 2015 Dec 5;2015(1):279-85. doi: 10.1182/asheducation-2015.1.279. PubMed PMID: 26637734.
  1. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17. PubMed PMID: 26282654.

 

 Hémopathie bégnine

Proposé par Milena Kohn et Vincent Allain, supervisé par Louis Terriou. 

  1. Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol [Internet]. 2016 Feb 1 [cited 2016 Jan 25];91(2):220–6. Available from: http://onlinelibrary.wiley.com/doi/10.1002/ajh.24242/abstract
  1. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial [Internet]. [cité 1 nov 2015]. Disponible sur: https://www-sciencedirect-com.frodon.univ-paris5.fr/science/article/pii/S0140673615611072
  1. Drug-Induced Megaloblastic Anemia — NEJM [Internet]. [cité 2 janv 2016]. Disponible sur: http://www.nejm.org/doi/full/10.1056/NEJMra1508861
  1. Wouters D, Zeerleder S. Complement inhibitors to treat IgM-mediated autoimmune hemolysis. Haematologica. 1 nov 2015;100(11):1388‑
  1. Fontbrune FS de, Moignet A, Beaupain B, Suarez F, Galicier L, Socié G, et al. Severe chronic primary neutropenia in adults: report on a series of 108 patients. 1 oct 2015;126(14):1643‑50.
  1. Brousseau DC, Scott JP, Badaki-Makun O, Darbari DS, Chumpitazi CE, Airewele GE, et al. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. 1 oct 2015;126(14):1651‑7.
  1. Brodsky RA. Complement in hemolytic anemia. Blood. 26 nov 2015;126(22):2459‑
  1. Expansion of inflammatory innate lymphoid cells in patients with common variable immune deficiency – Journal of Allergy and Clinical Immunology [Internet]. [cité 3 janv 2016]. Disponible sur: http://www.jacionline.org/article/S0091-6749(15)01351-2/abstract
  1. Wang Y, Huang W, Hu L, Cen X, Li L, Wang J, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 5 nov 2015;126(19):2186‑
  1. Taylor A, Neave L, Solanki S, Westwood JP, Terrinonive I, McGuckin S, et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. British Journal of Haematology. 15 nov 2015;171(4):625‑
  1. Gualandro SFM, Fonseca GHH, Yokomizo IK, Gualandro DM, Suganuma LM. Cohort study of adult patients with haemoglobin SC disease: clinical characteristics and predictors of mortality. British Journal of Haematology. 15 nov 2015;171(4):631‑

 

Hémostase

Proposé par Nicolas Gendron et Clémence Roux, supervisé par David Smadja. 

  1. Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, et al. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. janv 2016;3(1):e12‑
  1. Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost JTH. 26 sept 2015;
  1. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 11 nov 2015;
  1. Carvalhosa AB, Aouba A, Damaj G, Canioni D, Brouzes C, Gyan E, et al. A French National Survey on Clotting Disorders in Mastocytosis. Medicine (Baltimore). oct 2015;94(40):e1414.
  1. Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, et al. Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. J Clin Oncol Off J Am Soc Clin Oncol. 23 déc 2015;
  1. Martin A-C, Berndt C, Calmette L, Philip I, Decouture B, Gaussem P, et al. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: An in-vitro study. Eur J Anaesthesiol. 8 sept 2015
  1. Hazendonk H c. a. m., Lock J, Mathôt R a. a., Meijer K, Peters M, Laros-van Gorkom B a. p., et al. Perioperative treatment of hemophilia A patients: Blood group O patients are at risk of bleeding complications. J Thromb Haemost. 1 déc 2015;n/a‑ n/a.
  1. Kogan I, Chap D, Hoffman R, Axelman E, Brenner B, Nadir Y. JAK-2 V617F mutation increases heparanase procoagulant activity. Thromb Haemost. 22 déc 2015;115(1):73‑
  1. Tuckuviene R, Ranta S, Albertsen BK, Andersson NG, Bendtsen MD, Frisk T, et al. Prospective study of thromboembolism in 1038 children with acute lymphoblastic leukemia – a Nordic Society of Pediatric Hematology and Oncology (NOPHO) study. J Thromb Haemost JTH. 26 déc 2015;
  1. Martinod K, Witsch T, Farley K, Gallant M, Remold-O’Donnell E, Wagner DD. Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model of deep vein thrombosis. J Thromb Haemost JTH. 29 déc 2015;

 

LLC

 Proposé par Florian Chevillon et Claire Bréal, supervisé par Loïc Ysebaert. 

  1. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O’Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. N Engl J Med. 2015 Dec 17;373(25):2425-37. doi: 10.1056/NEJMoa1509388. Epub 2015 Dec 6.
  1. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M. Blood. 2016 Jan 14;127(2):208-15. doi: 10.1182/blood-2015-06-651125. Epub 2015 Oct 20.
  1. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.O’Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. Blood. 2015 Dec 17;126(25):2686-94. doi: 10.1182/blood-2015-03-630947. Epub 2015 Oct 15.
  1. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Enschede SH, Humerickhouse RA, Wierda WG, Seymour JF. N Engl J Med. 2015 Dec 6.
  1. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. N Engl J Med. 2015 Dec 7.
  1. Bendamustine and Rituximab in Combination with Lenalidomide in Patients with Chronic Lymphocytic Leukemia. Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink AM, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Böttcher S, Döhner H, Kneba M, Dreyling M, Binder M, Hallek M, Wendtner CM, Bergmann M, Fischer K; German CLL Study Group. Eur J Haematol. 2015 Dec 8.
  1. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Lancet Oncol. 2015 Dec 4.
  1. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Lipsky AH, Farooqui MZ, Tian X, Martyr S, Cullinane AM, Nghiem K, Sun C, Valdez J, Niemann CU, Herman SE, Saba N, Soto S, Marti G, Uzel G, Holland SM, Lozier JN, Wiestner A. Haematologica. 2015 Dec
  1. Inter- and intra-patient clonal and subclonal heterogeneity of chronic lymphocytic leukaemia: evidences from circulating and lymph nodal compartments. Del Giudice I, Marinelli M, Wang J, Bonina S, Messina M, Chiaretti S, Ilari C, Cafforio L, Raponi S, Mauro FR, Di Maio V, De Propris MS, Nanni M, Ciardullo C, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R. Br J Haematol. 2015 Nov 24
  1. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, Burger JA, Rai KR, Chiorazzi N. Leukemia. 2015 Nov 9